Sanofi
Sanofi, a global healthcare leader headquartered in France, is renowned for its commitment to improving health and well-being. Founded in 2004 through the merger of Sanofi-Synthélabo and Aventis, the company has established a strong presence in key operational regions, including Europe, North America, and Asia. Operating within the pharmaceutical and biotechnology industry, Sanofi focuses on several main business areas, including prescription medicines, vaccines, and consumer healthcare products. Its core offerings, such as innovative treatments for diabetes, rare diseases, and vaccines, are distinguished by their scientific rigor and patient-centric approach. With a robust market position, Sanofi has achieved notable milestones, including advancements in immunology and oncology, solidifying its reputation as a trusted name in global health solutions.
DitchCarbon Score
How does Sanofi's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Sanofi's score of 85 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Sanofi's reported carbon emissions
In 2022, Sanofi reported total carbon emissions of approximately 536,804,000 kg CO2e, which includes 332,470,000 kg CO2e from Scope 1 and 332,149,000 kg CO2e from Scope 2 emissions. The company has set ambitious climate commitments, aiming for net-zero greenhouse gas emissions across its entire value chain by FY2045, using FY2019 as the baseline year. Sanofi has established near-term targets to reduce absolute Scope 1 and 2 emissions by 55% by FY2030 and to increase its annual sourcing of renewable electricity from 11% in FY2019 to 80% by FY2025 and 100% by FY2030. Additionally, the company aims to cut absolute Scope 3 emissions by 30% by FY2030, which encompasses emissions from purchased goods and services, capital goods, and other operational activities. Long-term, Sanofi is committed to a 90% reduction in absolute emissions across Scope 1, 2, and 3 by FY2045. These targets align with the Science Based Targets initiative (SBTi) and reflect the company's commitment to addressing climate change within the pharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2010 | 2011 | 2012 | 2013 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 536,712,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 689,058,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | 000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Sanofi is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
